G
Giovanni Fornaciari
Researcher at University of Parma
Publications - 33
Citations - 2170
Giovanni Fornaciari is an academic researcher from University of Parma. The author has contributed to research in topics: Inflammatory bowel disease & Ulcerative colitis. The author has an hindex of 18, co-authored 33 publications receiving 1960 citations.
Papers
More filters
Journal ArticleDOI
Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis
Erica Villa,Calogero Cammà,Marco Marietta,Monica Luongo,Rosina Maria Critelli,Stefano Colopi,Cristina Tata,Ramona Zecchini,Stefano Gitto,Salvatore Petta,Barbara Lei,Veronica Bernabucci,Ranka Vukotic,Nicola De Maria,Filippo Schepis,Aimilia Karampatou,Cristian Caporali,Luisa Simoni,Mariagrazia Del Buono,Beatrice Zambotto,Elena Turola,Giovanni Fornaciari,Susanna Schianchi,Anna Ferrari,Dominique Valla,Dominique Valla +25 more
TL;DR: In this article, a randomized controlled trial was performed to evaluate the safety and efficacy of enoxaparin, a low-molecular-weight heparin, in preventing portal vein thrombosis (PVT) in patients with advanced cirrhosis.
Journal Article
Enoxaparin Prevents Portal Vein Thrombosisand Liver Decompensation in Patients With Advanced Cirrhosis.
Calogero Cammà,Salvatore Petta,Cristina Tata,Mariagrazia Del Buono,Filippo Schepis,Monica Luongo,Nicola De Maria,Marco Marietta,Giovanni Fornaciari,Barbara Lei,Dominique Valla,Dominique Valla,Stefano Colopi,Veronica Bernabucci,Ranka Vukotic,Stefano Gitto,Rosina Maria Critelli,Aimilia Karampatou,Elena Turola,Erica Villa,Luisa Simoni,Susanna Schianchi,Beatrice Zambotto,Ramona Zecchini,Cristian Caporali,Anna Ferrari +25 more
TL;DR: In a small randomized controlled trial, a 12-month course of enoxaparin was safe and effective in preventing PVT in patients with cirrhosis and a Child-Pugh score of 7-10 and to improve survival.
Journal ArticleDOI
Cost Analysis and Cost Determinants in a European Inflammatory Bowel Disease Inception Cohort With 10 Years of Follow-up Evaluation
Selwyn Odes,Hillel Vardi,Michael Friger,Frank Wolters,Maurice G. Russel,Lene Riis,Pia Munkholm,P. Politi,Epameinondas V. Tsianos,Juan Clofent,Severine Vermeire,Estela Monteiro,Iannis Mouzas,Giovanni Fornaciari,Jildou Sijbrandij,Charles Limonard,Gilbert Van Zeijl,Colm O'Morain,Bjørn Moum,Morten H. Vatn,Reinhold W. Stockbrügger +20 more
TL;DR: In this multinational, population-based, time-dependent characterization of the health care cost of inflammatory bowel disease, increased expenditure was driven largely by country, diagnosis, hospitalization, and follow-up year.
Journal ArticleDOI
Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients.
Carlo Salvarani,Ioannis G. Vlachonikolis,D. van der Heijde,Giovanni Fornaciari,Pierluigi Macchioni,M Beltrami,I. Olivieri,F. di Gennaro,P. Politi,Reinhold W. Stockbrügger,Maurice G. Russel +10 more
TL;DR: The study shows a high prevalence of musculoskeletal manifestations in an inception cohort of IBD patients and the clinical spectrum is broader than that defined by spondylarthropathy criteria.
Journal ArticleDOI
Crohn’s disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort
Frank Wolters,Maurice G. Russel,Jildou Sijbrandij,Leo J. Schouten,Selwyn Odes,Lene Riis,Pia Munkholm,Paolo Bodini,Colm O'Morain,Ioannis A. Mouzas,Epameinondas V. Tsianos,Severine Vermeire,Estela Monteiro,Charles Limonard,Morten H. Vatn,Giovanni Fornaciari,Santos Pereira,Bjørn Moum,Reinhold W. Stockbrügger +18 more
TL;DR: This European multinational population based study revealed an increased overall mortality risk in CD patients 10 years after diagnosis, and age above 40 years at diagnosis was found to be the sole factor associated with increased mortality risk.